Allergens and infections with parasitic helminths preferentially induced Th2 immune responses associated with elevated levels of serum immunoglobulin E (IgE) and expansion of eosinophils and mast cells. Interleukin-4 (IL-4) is a key cytokine in the differentiation of naive CD4+ T cells into Th2 cells, which produce a panel of cytokines including IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13 [1] and have been shown to trigger recovery from gastrointestinal nematodes [2]. Nonetheless, mice deficient for IL-4 have been shown to develop residual Th2 responses [3-5] and can expel the nematode Nippostrongylus brasiliensis [6], suggesting that there is a functional equivalent of IL-4 in these processes. IL-13 is a cytokine that shares some, but not all, biological activities with IL-4 [7,8]. There is now compelling evidence that IL-4 and IL-13 share receptor components, including IL-4R alpha and IL-13R alpha 1 [9]. In order to dissect the roles of IL-4 and IL-13 in the regulation of Th2 cells and in the response to nematode infections, we looked for differences between mice deficient for either the IL-4 gene or the IL-4R alpha gene. Unlike IL-4, IL-4R alpha was required for control of N. brasiliensis, and Th2 development during infection--as characterized by cytokine production, GATA-3 and surface CD30 expression--was more severely affected in IL-4R alpha-/- mice than in IL-4-/- mice. Injection of recombinant IL-13 induced worm expulsion in otherwise incompetent RAG2-/- mice. Our results suggest that IL-13 regulates Th2 responses to nematode infection and requires IL-4R alpha.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-9822(98)70256-8DOI Listing

Publication Analysis

Top Keywords

il-4r alpha
16
th2 responses
12
il-4
9
il-13 regulation
8
regulation th2
8
th2 cells
8
mice deficient
8
deficient il-4
8
il-4 il-13
8
il-13
7

Similar Publications

Article Synopsis
  • - Current treatments for autoimmune diseases often fail to achieve long-term remission, prompting interest in therapies that restore balance in the immune system, known as immune resolution; however, there's no clear consensus on how to evaluate these therapies in clinical trials.
  • - A systematic literature review (SLR) was conducted using established guidelines to explore expert opinions and previous studies on immune resolution in five autoimmune diseases: asthma, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, and ulcerative colitis; this involved searching databases and conference proceedings from 2013 to 2023.
  • - The SLR included 26 publications and found that expert opinions tended to lack specific measures for assessing immune resolution but suggested potential targets and biomarkers for future therapy
View Article and Find Full Text PDF
Article Synopsis
  • Severe asthma is a chronic condition that current treatments struggle to manage, and Thymic stromal lymphopoietin (TSLP) plays a crucial role in its development, indicating the potential of blocking TSLP for treatment.
  • The study developed a new humanized anti-TSLP antibody called QX008N, which showed high efficacy in stopping TSLP-induced inflammation and improved lung function in animal models when used alone and in combination with anti-IL-4R antibodies.
  • The findings suggest that targeting both TSLP and IL-4R pathways may offer a more effective treatment strategy for asthma, providing strong preclinical support for these combination therapies.
View Article and Find Full Text PDF

A multifunctional antibody fusion protein 57103 targeting CD24, IL-4R, and αβ for treating cancer and regulating the tumor microenvironment.

Biomed Pharmacother

June 2024

State Key Laboratory of Natural Medicines, Ministry of Education, the Engineering Research Center of Synthetic Polypeptide Drug Discovery and Evaluation of Jiangsu Province, Department of Marine Pharmacy, China Pharmaceutical University, Nanjing 211198, China; The Engineering Research Center of Synthetic Peptide Drug Discovery and Evaluation of Jiangsu Province, China Pharmaceutical University, Nanjing 210009, China. Electronic address:

Article Synopsis
  • Cancer ranks as one of the deadliest diseases globally, with advanced metastatic carcinoma leading in mortality, highlighting the urgent need for new targeted therapies.
  • Researchers developed a novel antibody fusion protein, 57103, which effectively targets multiple receptors and exhibited significant anti-cancer effects in vitro by suppressing the growth, migration, and invasion of renal cancer cells.
  • In animal studies, 57103 demonstrated the ability to inhibit tumor growth and promote cancer cell death while also improving immune responses, indicating its potential as a treatment for metastatic renal carcinoma or other cancers that overexpress PDL1.
View Article and Find Full Text PDF
Article Synopsis
  • Triple-negative breast cancer (TNBC) is associated with high levels of M2-like macrophages (TAMs), which worsen cancer progression and prognosis.
  • CD44v5 is highly expressed in TNBC cells and plays a crucial role in promoting metastasis by interacting with IL4Rα, activating the STAT3/IL6 signaling pathway and influencing TAM polarization.
  • Targeting the CD44v5 domain could be a potential strategy for regulating the tumor microenvironment and developing treatments for TNBC.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!